N@N

Andrew Fein Maintained (AMLX) at Strong Buy with Increased Target to $50 on, Oct 24th, 2022

^{Published on 2024-10-27 23:34:57 - WOPRAI, Andrew Fein}
 

Andrew Fein of HC Wainwright & Co., Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy with Increased Target from $35 to $50 on, Oct 24th, 2022.

Andrew has made no other calls on AMLX in the last 4 months.

There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Chris Shibutani of "Goldman Sachs" Maintained at Hold with Increased Target to $40 on, Friday, September 9th, 2022

These are the ratings of the 2 analyists that currently disagree with Andrew

---

• Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Increased Target to $50 on, Monday, October 3rd, 2022
• Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $50 on, Thursday, September 8th, 2022

Contributing Sources

---